Tandem Diabetes Care shares rise 1.63% after-hours following Junshi Biosciences' 49% revenue increase.

Tandem Diabetes Care, Inc. rose 1.63% in after-hours trading. Junshi Biosciences, a leading biopharmaceutical company, announced its 2025 interim financial results, reporting a 49% increase in total revenue for the first half of 2025, driven mainly by pharmaceutical sales. The domestic sales revenue of their core product, TUOYI® (toripalimab), reached approximately RMB954 million, an increase of approximately 42% from the previous year.